Modest overall survival improvements from 1998 to 2009 in metastatic gastric cancer patients: a population-based SEER analysis

Abstract

On a population-based level, only modest improvements in prognosis for metastatic gastric cancer were observed in patients who underwent and in patients who did not undergo palliative gastrectomy. Considering the low rate of midterm survivors in both groups, only a small subgroup of patients benefits from palliative gastrectomy.

Efficacy of endoscopic management of leak after foregut surgery with endoscopic covered self-expanding metal stents (SEMS)

“…Keywords Endoscopic stent Á Anastomotic leak Á Esophageal leak Á Self-expandable metal stent Á Leak management Á Bariatric surgery Surgical therapy for obesity as well as both esophageal and gastric malignancy is commonly performed procedures worldwide [1][2][3][4]. While there have been improvements in clinical outcomes in recent years, anastomotic and stapleline leaks remain a potentially deadly complication of foregut surgery associated with significant morbidity and mortality and have been reported at rates up to 10 % of the time [5][6][7][8][9][10].…”

The role of surgical resection before palliative chemotherapy in advanced gastric cancer

“…However, the role of palliative surgical resection is still controversial in general treatment practice for RPMGC. Previous retrospective studies [4][5][6][7][8][9][10][11][12][13] , meta-analysis [14][15][16][17] , and population based analysis [18][19][20][21][22] have suggested that the addition of surgical resection to chemotherapy may have a survival benefit in RPMGC. However, the only randomized phase III trial, the REGATTA study 3 , failed to prove a survival benefit of gastrectomy followed by chemotherapy compared with chemotherapy alone in primary metastatic gastric cancer patients.…”

Regional Variation in the Management of Metastatic Gastric Cancer in Ontario

“…Hospitalizations represent a major contributor to costs, and there is little understanding of how other resource utilization factors contribute to those high costs 15,16,18 . Variations in prognosis for metastatic gastric cancer patients have been identified between geographic areas in many low-incidence countries and within single health systems, and whether variation in clinical practice is a contributing factor is unknown [19][20][21] . Few investigations of regional variation for the most common treatment modalities (gastrectomy, chemotherapy, radiotherapy) have been published 21,22 .…”

“…Variations in prognosis for metastatic gastric cancer patients have been identified between geographic areas in many low-incidence countries and within single health systems, and whether variation in clinical practice is a contributing factor is unknown [19][20][21] . Few investigations of regional variation for the most common treatment modalities (gastrectomy, chemotherapy, radiotherapy) have been published 21,22 . One North American study reported that the proportion of patients receiving noncurative surgery was similar across geographic regions 22 .…”

“…One North American study reported that the proportion of patients receiving noncurative surgery was similar across geographic regions 22 . A study using the U.S. Surveillance, Epidemiology, and End Results database reported a resection rate of 17% for metastatic patients and a 10% rate of radiotherapy use 21 .…”